Immunocore
IMCR
142 hedge funds and large institutions have $1.58B invested in Immunocore in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 44 reducing their positions, and 28 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 44
1.33% more ownership
Funds ownership: 102.02% → 103.35% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 149 → 142 (-7)
12% less capital invested
Capital invested by funds: $1.79B → $1.58B (-$209M)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
88% less call options, than puts
Call options by funds: $6.02M | Put options by funds: $49.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$70.6M |
| 2 |
Two Sigma Investments
New York
|
+$21.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$21M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.3M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$18.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$132M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$51.4M |
| 3 |
Primecap Management
Pasadena,
California
|
-$8.69M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$6.29M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$5.08M |
IMCR Hedge Fund Activity: Q1 2026 in Review
142 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q1 2026, worth a combined $1.58B — down 12% from $1.79B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of IMCR and 23 opened new positions — a net loss of 5 holders — while 44 trimmed existing stakes and 51 added.
The largest buyer was Vestal Point Capital, adding an estimated $70.6M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $132M.
- 142 institutional investors held Immunocore (IMCR) as of Q1 2026, down from 149 in Q4 2025.
- Funds reported $1.58B of Immunocore stock for Q1 2026, down 12% quarter-over-quarter.
- 23 funds opened new Immunocore positions in Q1 2026 and 28 closed out, a net change of -5 holders.
- The largest Immunocore buyer in Q1 2026 was Vestal Point Capital, an estimated $70.6M added.
- The largest Immunocore seller in Q1 2026 was T. Rowe Price Investment Management, an estimated $132M sold.
Based on aggregated 13F filings for Q1 2026.